Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079833 · ClinicalTrials.gov registry record · Phase 3
Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
NCT00079833 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 25 participants.
The verdict
NCT00079833, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
Study Summary
This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.
Interventions
- DRUG Esomeprazole magnesium (Nexium)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2003-11 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079833
The ClinicalTrials.gov registry entry for NCT00079833 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Esomeprazole magnesium (Nexium) is the first listed.
NCT00079833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00079833 about?
NCT00079833 is a clinical study titled "Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome". This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.
What is the current status of trial NCT00079833?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2003-11. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00079833?
The interventions under investigation include: Esomeprazole magnesium (Nexium) (DRUG).
Who is sponsoring clinical trial NCT00079833?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.